Cell Line Data Sheet for CHLA-136

Disease:	Neuroblastoma
Phase of Therapy:	Post-Chemotherapy (Progressive Disease), Post-bone marrow transplant
Treatment:	N/A
Disease Stage:	4
Gender:	Female
Age at diagnosis:	36 months
Race:	N/A
Age at sample collection:	N/A
Source of Culture:	Blood
Primary Tumor Site:	N/A
Date Established:	November 1993
MYCN Patient:	Amplified
MYCN Cell line:	N/A
THmRNA:	Expressed
p53 functionality:	Functional
Telomere Mechanism:	N/A
ALK:	WT
RNAseq:	N/A
WES:	N/A
Growth Conditions:	Please see Protocols section at https://www.cccells.org/protocols.php 5% CO_2, 20% O_2, 37.0°C
Media Formulation:	Please see Protocols section at https://www.cccells.org/protocols.php Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)
Doubling Time:	44 hours
Growth Properties:	Suspended, grow mostly in tight clumps, also a small population of attached cells
STR Profile:	May be obtained at https://strdb.cccells.org/
Notes:	The Childhood Cancer Repository has a diagnosis (pre-therapy) cell line available from this same patient (CHLA-122)

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis

Cell Line Data Sheet for CHLA-136

Cell Line Name: **CHLA-136**

References:

Reynolds C P: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. *Cancer Res.* 61:6185-6193, 2001. PubMed ID: 11507071
https://cancerres.aacrjournals.org/content/61/16/6185.long

2. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. Cancer Res. 61, 679-686, 2001. PubMed ID: 11212268
https://cancerres.aacrjournals.org/content/61/2/679.long

3. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide. *J Natl Cancer I.* 99: 1107-19, 2007. PubMed ID: 17623797
https://academic.oup.com/jnci/article/99/14/1107/938992

4. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer*. 56: 239-249, 2011. PubMed ID: 20922763
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/

1. Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche TJ,

(www.PPTPinvitro.org)

5. B. Koneru, G. Lopez,A170:E170 A. Farooqi, K. L. Conkrite, T. H. Nguyen, S. J. Macha, A. Modi, J. L. Rokita, E. Urias, A. Hindle, H. Davidson, K. McCoy, J. Nance, V. Yazdani, M. S. Irwin, S. Yang, D. A. Wheeler, J. M. Maris, S. J. Diskin, C. P. Reynolds, Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Res. 2020;80:2663-2675." PMID 32291317

https://cancerres.aacrjournals.org/content/80/12/2663.long

Cell Line Data Sheet for CHLA-136

Low confluency (10x magnification)



High confluency (10x magnification)



Low confluency (20x magnification)



High confluency (20x magnification)